This trial is for the Ewing’s sarcoma family of tumours. The aim is to compare two chemotherapy regimens to see which is more effective. The two treatment regimens are the VIDE strategy (vincristine, ifosfamide, doxorubicin and etoposide (VIDE) chemotherapy followed by vincristine, actinomycin D and ifosfamide/cyclophosphamide (VAI/VAC) or busulfan and melphalan (VAI/BuMel)), and the VDC/IE strategy (alternating cycles of vincristine, cyclophosphamide, doxorubicin (VDC) and ifosfamide, etoposide (IE) chemotherapy and followed by cycles of ifosfamide, etoposide (IE) and vincristine, cyclophosphamide (VC) or busulfan and melphalan (VAI/BuMel)). The second aim of the trial is to see if giving a drug called zoledronic acid with this chemotherapy can improve treatment.
| Chief Investigator: |
Professor Bernadette Brenan |
| Sponsor: |
University of Birmingham |
| Funders: |
Cancer Research UK (CRUK) and the European Union’s Seventh Framework Programme |
| Disease Site: |
Ewing's Sarcoma |
| Trial Type: |
Clinical Trial of an Investigational Medical Product |
| Status: |
Closed to recruitment |
| UKCRN Study ID: (if applicable) |
13804 |
| Open to new sites? |
No |
| Recruitment start date: |
December 2013 |
| Recruitment end date |
May 2019 |
| CRCTU Trial Management Team: |
Children's Cancer Trials Team |
| Trial E-mail Address: |
ee2012@trials.bham.ac.uk |